Frontiers in Medicine (Jul 2021)

Case Report: Human Umbilical Cord Mesenchymal Stem Cells as a Therapeutic Intervention for a Critically Ill COVID-19 Patient

  • Quan Zhang,
  • Kang Huang,
  • Jianlei Lv,
  • Xiang Fang,
  • Jun He,
  • Ailian Lv,
  • Xuan Sun,
  • Xuan Sun,
  • Lamei Cheng,
  • Lamei Cheng,
  • Yanjun Zhong,
  • Shangjie Wu,
  • Yao Dai

DOI
https://doi.org/10.3389/fmed.2021.691329
Journal volume & issue
Vol. 8

Abstract

Read online

Here we report a critically ill patient who was cured of SARS-CoV-2 infection in Changsha, China. A 66-year-old Chinese woman, with no significant past medical history, developed severe pneumonia-like symptoms and later diagnosed as severe COVID-19 pneumonia. Within 2 months of hospitalization, the patient deteriorated to ARDS including pulmonary edema and SIRS with septic shock. When treatment schemes such as antibiotics plus corticosteroids showed diminished therapeutic value, hUCMSC therapy was compassionately prescribed under the patient's consent of participation. After treatment, there was significant improvement in disease inflammation-related indicators such as IL-4, IL-6, and IL-10. Eventually, it confirmed the therapeutic value that hUCMSCs could dampen the cytokine storm in the critically ill COVID-19 patient and modulated the NK cells. In the continued hUCMSC treatment, gratifying results were achieved in the follow-up of the patient. The data we acquired anticipate a significant therapeutic value of MSC treatment in severe and critically ill patients with COVID-19, while further studies are needed.

Keywords